Recent News

• 06.11.2025 - Jazz Pharmaceuticals at the 46th Annual Goldman Sachs Healthcare Conference
• 06.11.2025 - Jazz Pharmaceuticals at the 46th Annual Goldman Sachs Healthcare Conference
• 06.10.2025 - Zepzelca ASCO Data Webcast
• 06.10.2025 - Zepzelca ASCO Data Webcast
• 06.10.2025 - Zepzelca ASCO Data Webcast
• 06.10.2025 - Zepzelca ASCO Data Webcast
• 06.10.2025 - Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer
• 06.10.2025 - Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer
• 06.09.2025 - Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025
• 06.09.2025 - Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025

Recent Filings

• 06.06.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 06.06.2025 - DEF 14A Other definitive proxy statements
• 06.06.2025 - ARS Annual Report to Security Holders
• 06.04.2025 - 4 Statement of changes in beneficial ownership of securities